Top-News
Pharmazeutika USA

Theriva Biologics Inc News

Aktie
WKN:  A3DMG6 ISIN:  US87164U4094 US-Symbol:  TOVX
0,404 €
+0,023 €
+6,04%
26.04.24 16:27:31
Handeln Depot/Watchlist
Aktienanzahl *
17,15 Mio.
Marktkapitalisierung *
6,50 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 09.04.2024

Theriva Biologics Inc News

25.07.22 - PR Newswire
Thinking about buying stock in Synthetic Biologics, Revelation Biosciences, Geovax Labs, Chimerix, or Zymergen?
Thinking about buying stock in Synthetic Biologics, Revelation Biosciences, Geovax Labs, Chimerix, or Zymergen? PR Newswire
09.02.22 - PR Newswire
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire
08.02.22 - PR Newswire
Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA
Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned ...
26.01.22 - PR Newswire
Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022
Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire
14.12.21 - PR Newswire
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors ...
03.11.21 - PR Newswire
Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple ...
26.10.21 - PR Newswire
Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021
Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, ...
21.10.21 - PR Newswire
Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase
Synthetic Biologics Announces Initiation of a Phase 1 Multiple-​Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 ...
06.10.21 - PR Newswire
Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have ...
21.09.21 - PR Newswire
Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire
05.08.21 - PR Newswire
Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-​Ascending Dose ...
28.07.21 - PR Newswire
Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021
Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021 Conference Call Scheduled for Thursday, August 5, 2021 at 4:30 ...
29.06.21 - PR Newswire
Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial
Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-​Ascending Dose Clinical Trial Orally Administered SYN-020 Observed to be Well ...
26.05.21 - PR Newswire
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire
28.04.21 - PR Newswire
Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021
Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021 -- Conference Call Scheduled for Wednesday, May 5, 2021 at 4:30 p.m. ...
14.04.21 - PR Newswire
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients PR Newswire
01.04.21 - PR Newswire
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase A Multiple-​Ascending Dose Study is on Track to ...
04.03.21 - PR Newswire
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results -- Announced Washington University Has Begun Screening Patients for Enrollment in ...
25.02.21 - PR Newswire
Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021
Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021 -- Conference Call Scheduled for Thursday, March 4, 2021 at 4:30 p.m. ...
22.12.20 - PR Newswire
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol IRB Approval Signals ...

Newssuche

Videos

08:55 Uhr -6,48%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »